In this AtheroTalk episode, Prof. Frederick Raal - a distinguished Professor at the University of the Witwatersrand and one of the world’s leading experts in familial hypercholesterolemia - shares insights from his clinical and research journey.He discusses balancing clinical duties with leading one of the largest HoFH cohorts globally, highlighting the importance of mentorship, curiosity, and disciplined time management.Prof. Raal explains the expanding role of PCSK9 and ANGPTL3 inhibitors, emphasizing combination therapy as essential for HoFH.He reflects also on unanswered questions regarding long-term safety of PCSK9 inhibitors, the promise and challenges of gene-editing approaches, and the urgent need to improve global access to advanced lipid-lowering therapies.---------------------------------------------------Script-prep: Fotios BarkasInterviewer: Fotios Barkas

Ver todos los episodios